Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonia Messina

Showing results (101-110 of 162) with videos related to

Pageof 17
Sort By:
Neuromuscular Disorders : NMD|March 28, 2021
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophyClaudia Brogna, Giorgia Coratti, Rachele Rossi, et al.
Acta Myologica : Myopathies and Cardiomyopathies : Official Journal of the Mediterranean Society of Myology|April 16, 2015
Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative studyLorenza Magliano, Maria Grazia D'Angelo, Giuseppe Vita, et al.
Brain : a Journal of Neurology|April 27, 2021
The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trialEleonora Dalla Bella, Enrica Bersano, Giovanni Antonini, et al.
Journal of Neurology|September 16, 2017
Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohortFrancesca Trojsi, Mattia Siciliano, Cinzia Femiano, et al.
The Lancet. Neurology|March 20, 2024
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialEugenio Mercuri, Juan J Vilchez, Odile Boespflug-Tanguy, et al.
BMC Neurology|February 25, 2017
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophyMaria C Pera, Giorgia Coratti, Nicola Forcina, et al.
Neurology|February 6, 2015
Prevalence of congenital muscular dystrophy in Italy: a population studyAlessandra Graziano, Flaviana Bianco, Adele D'Amico, et al.
Eclinicalmedicine|May 17, 2023
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapiesMarika Pane, Beatrice Berti, Anna Capasso, et al.
Neuromuscular Disorders : NMD|January 19, 2016
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trialsEugenio Mercuri, Richard Finkel, Jacqueline Montes, et al.
Frontiers in Neuroscience|June 4, 2019
Comparative Analysis of <i>C9orf72</i> and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of <i>C9orf72</i> Positive PatientsFrancesca Trojsi, Mattia Siciliano, Cinzia Femiano, et al.
Pageof 17

Showing results (101-110 of 162) with videos related to

Sort By:
Pageof 17
Neuromuscular Disorders : NMD|March 28, 2021
The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophyClaudia Brogna, Giorgia Coratti, Rachele Rossi, et al.
Acta Myologica : Myopathies and Cardiomyopathies : Official Journal of the Mediterranean Society of Myology|April 16, 2015
Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative studyLorenza Magliano, Maria Grazia D'Angelo, Giuseppe Vita, et al.
Brain : a Journal of Neurology|April 27, 2021
The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trialEleonora Dalla Bella, Enrica Bersano, Giovanni Antonini, et al.
Journal of Neurology|September 16, 2017
Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohortFrancesca Trojsi, Mattia Siciliano, Cinzia Femiano, et al.
The Lancet. Neurology|March 20, 2024
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialEugenio Mercuri, Juan J Vilchez, Odile Boespflug-Tanguy, et al.
BMC Neurology|February 25, 2017
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophyMaria C Pera, Giorgia Coratti, Nicola Forcina, et al.
Neurology|February 6, 2015
Prevalence of congenital muscular dystrophy in Italy: a population studyAlessandra Graziano, Flaviana Bianco, Adele D'Amico, et al.
Eclinicalmedicine|May 17, 2023
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapiesMarika Pane, Beatrice Berti, Anna Capasso, et al.
Neuromuscular Disorders : NMD|January 19, 2016
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trialsEugenio Mercuri, Richard Finkel, Jacqueline Montes, et al.
Frontiers in Neuroscience|June 4, 2019
Comparative Analysis of <i>C9orf72</i> and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of <i>C9orf72</i> Positive PatientsFrancesca Trojsi, Mattia Siciliano, Cinzia Femiano, et al.
Pageof 17